Literature DB >> 24975812

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.

Julia Scheiermann1, Dennis M Klinman2.   

Abstract

Synthetic oligonucleotides (ODN) that express unmethylated "CpG motifs" trigger cells that express Toll-like receptor 9. In humans this includes plasmacytoid dendritic cells and B cells. CpG ODN induce an innate immune response characterized by the production of Th1 and pro-inflammatory cytokines. Their utility as vaccine adjuvants was evaluated in a number of clinical trials. Results indicate that CpG ODN improve antigen presentation and the generation of vaccine-specific cellular and humoral responses. This work provides an up-to-date overview of the utility of CpG ODN as adjuvants for vaccines targeting infectious agents and cancer. Published by Elsevier Ltd.

Entities:  

Keywords:  Adjuvant; Cancer; CpG olignucleotide; Infection; Toll-like receptor

Mesh：

Substances：

Year:  2014        PMID： 24975812      PMCID： PMC4252359          DOI： 10.1016/j.vaccine.2014.06.065

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  143 in total

1.  Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations.

Authors:  Daniel C Freed; Victoria M Towne; Danilo R Casimiro; Qinjian Zhao; Tong-Ming Fu
Journal:  Vaccine       Date:  2011-10-11       Impact factor: 3.641

Review 2.  Clinical evaluation of TRICOM vector therapeutic cancer vaccines.

Authors:  Ravi A Madan; Marijo Bilusic; Christopher Heery; Jeffrey Schlom; James L Gulley
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

3.  Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.

Authors:  D Verthelyi; K J Ishii; M Gursel; F Takeshita; D M Klinman
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

4.  CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans.

Authors:  H L Davis; I I Suparto; R R Weeratna; D D Iskandriati; S S Chamzah; A A Ma'ruf; C C Nente; D D Pawitri; A M Krieg; W Smits; D D Sajuthi
Journal:  Vaccine       Date:  2000-03-17       Impact factor: 3.641

5.  Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.

Authors:  Ahmad A Tarhini; Siyang Leng; Stergios J Moschos; Yan Yin; Cindy Sander; Yan Lin; William E Gooding; John M Kirkwood
Journal:  J Immunother       Date:  2012-05       Impact factor: 4.456

6.  Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

Authors:  J N Cormier; M L Salgaller; T Prevette; K C Barracchini; L Rivoltini; N P Restifo; S A Rosenberg; F M Marincola
Journal:  Cancer J Sci Am       Date:  1997 Jan-Feb

7.  Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis.

Authors:  T Sparwasser; L Hültner; E S Koch; A Luz; G B Lipford; H Wagner
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

8.  The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali.

Authors:  Boubacar Traore; Younoussou Koné; Safiatou Doumbo; Didier Doumtabé; Abdramane Traoré; Peter D Crompton; Marko Mircetic; Chiung-Yu Huang; Kassoum Kayentao; Alassane Dicko; Issaka Sagara; Ruth D Ellis; Kazutoyo Miura; Agnes Guindo; Louis H Miller; Ogobara K Doumbo; Susan K Pierce
Journal:  Vaccine       Date:  2009-08-25       Impact factor: 3.641

9.  Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase.

Authors:  Sarah E Ewald; Alex Engel; Jiyoun Lee; Miqi Wang; Matthew Bogyo; Gregory M Barton
Journal:  J Exp Med       Date:  2011-03-14       Impact factor: 14.307

10.  TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults.

Authors:  Rasmus Offersen; Jesper Melchjorsen; Søren R Paludan; Lars Østergaard; Martin Tolstrup; Ole S Søgaard
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452
View more
  113 in total

Review 1.  Translating nucleic acid-sensing pathways into therapies.

Authors:  Tobias Junt; Winfried Barchet
Journal:  Nat Rev Immunol       Date:  2015-08-21       Impact factor: 53.106

Review 2.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

3.  Investigations into the efficacy of multi-component cocaine vaccines.

Authors:  Atsushi Kimishima; Margaret E Olson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-12-20       Impact factor: 2.823

4.  Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.

Authors:  Sakineh Pirahmadi; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Abbas-Ali Raz; Jafar J Sani
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

5.  TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall.

Authors:  Marcin Cebula; Mathias Riehn; Upneet Hillebrand; Ramona F Kratzer; Florian Kreppel; Georgia Koutsoumpli; Toos Daemen; Hansjörg Hauser; Dagmar Wirth
Journal:  Mol Ther       Date:  2017-07-14       Impact factor: 11.454

6.  Therapeutic implications of orally delivered immunomodulatory oligonucleotides.

Authors:  Dennis M Klinman
Journal:  Mol Ther       Date:  2015-02       Impact factor: 11.454

Review 7.  Veterinary vaccine nanotechnology: pulmonary and nasal delivery in livestock animals.

Authors:  Daniella Calderon-Nieva; Kalhari Bandara Goonewardene; Susantha Gomis; Marianna Foldvari
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

8.  Cutaneous vaccination with coated microneedles prevents development of airway allergy.

Authors:  Akhilesh Kumar Shakya; Chang Hyun Lee; Harvinder Singh Gill
Journal:  J Control Release       Date:  2017-08-15       Impact factor: 9.776

9.  Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.

Authors:  Mariela A Moreno Ayala; María Florencia Gottardo; María Soledad Gori; Alejandro Javier Nicola Candia; Carla Caruso; Andrea De Laurentiis; Mercedes Imsen; Slobodanka Klein; Elisa Bal de Kier Joffé; Gabriela Salamone; Maria G Castro; Adriana Seilicovich; Marianela Candolfi
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-21       Impact factor: 4.553

10.  CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.

Authors:  Marie Jordan; David J Waxman
Journal:  Cancer Lett       Date:  2015-12-03       Impact factor: 8.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.